These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26411412)

  • 1. Cytochrome P450 in Cancer Susceptibility and Treatment.
    Mittal B; Tulsyan S; Kumar S; Mittal RD; Agarwal G
    Adv Clin Chem; 2015; 71():77-139. PubMed ID: 26411412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance.
    Ragia G; Giannakopoulou E; Karaglani M; Karantza IM; Tavridou A; Manolopoulos VG
    Drug Metabol Drug Interact; 2014; 29(4):235-48. PubMed ID: 24756055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH
    Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs.
    Rodríguez Arcas MJ; García-Jiménez E; Martínez-Martínez F; Conesa-Zamora P
    Farm Hosp; 2011; 35(2):84-92. PubMed ID: 21093338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.
    Ravyn D; Ravyn V; Lowney R; Nasrallah HA
    Schizophr Res; 2013 Sep; 149(1-3):1-14. PubMed ID: 23870808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of CYP450 and cancer susceptibility.
    Han XM; Zhou HH
    Acta Pharmacol Sin; 2000 Aug; 21(8):673-9. PubMed ID: 11501173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
    Daly AK
    Adv Pharmacol; 2015; 74():85-111. PubMed ID: 26233904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interaction between CYP450 enzymes and metabolism of traditional Chinese medicine as well as enzyme activity assay].
    Lu TL; Su LL; Ji D; Gu W; Mao CQ
    Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3524-9. PubMed ID: 26983193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.
    Tulsyan S; Agarwal G; Lal P; Mittal B
    Clin Chim Acta; 2014 Jul; 434():21-8. PubMed ID: 24768782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.
    Song X; Varker H; Eichelbaum M; Stopfer P; Shahidi M; Wilson K; Kaiser R; Finnern HW
    Lung Cancer; 2011 Oct; 74(1):103-11. PubMed ID: 21382644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.
    Ingelman-Sundberg M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):89-104. PubMed ID: 14574440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytochrome p450 and their implication in chemotherapy].
    Delwaide PA
    Rev Med Liege; 1998 Nov; 53(11):700-10. PubMed ID: 9887664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.
    Pilgrim JL; Gerostamoulos D; Drummer OH
    Forensic Sci Med Pathol; 2011 Jun; 7(2):162-84. PubMed ID: 21052868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.